Postoperative application of multidisciplinary treatment in patients with hepatobiliary and pancreatic malignancies
10.3969/j.issn.1001-5256.2015.11.028
- VernacularTitle:多学科协作诊治在肝胆胰恶性肿瘤术后应用的可行性分析
- Author:
Xiaoju SHI
1
;
Guoyue LYU
;
Ping ZHANG
Author Information
1. Department of Hepatic-Biliary-Pancreatic Surgery, The First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Research Article
- Keywords:
liver neoplasms;
biliary tract neoplasms;
pancreatic neoplasms;
antineoplastic protocols;
combined modality therapy
- From:
Journal of Clinical Hepatology
2015;31(11):1886-1888
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate postoperative application of multidisciplinary treatment (MDT) in hepatobiliary and pancreatic malignancies based on the pathological results. MethodsThe clinical data of patients who were diagnosed as hepatobiliary and pancreatic malignancies who were diagnosed and treated with postoperative MDT in our hospital from Apirl 2014 to March 2015 were analyzed. MDT was performed by consultation for four to six patients once every other week. The postoperative comprehensive treatment strategy for each patient was discussed and determined by all experts in the consultation. The effect of postoperative treatment and prognosis was summarized . Results25 postoperative MDT consultations on hepatobiliary and pancreatic malignancies were held for 131 patients, including 53 patients with hepatocellular carcinoma, 7 patients with intrahepatic cholangiocarcinoma, one patient with mixed-type liver cancer, 3 patients with metastatic liver cancer, 2 patients with liver sarcoma, 29 patients with extrahepatic cholangiocarcinoma, 22 patients with pancreatic cancer, 5 patients with gallbladder cancer, and 9 patients with periampullary cancer. After surgery, 38 patients received interventional treatment, 19 systemic chemotherapy, 15 radiotherapy, 17 cell biotherapy, and 5 molecularly targeted therapy. The case fatality rate was 2.29%（3/131）. ConclusionPostoperative MDT provides scientific and rational personalized comprehensive treatment for patients with hepatobiliary and pancreatic malignancies, and improves medication compliance in patients, which holds promise for wide application.
